Taking on board higher near-term expenses
22/06/22 -"However, these expenses are investment into growth and should continue to support Astra’s sector-leading top-line growth in the coming years. Overall, our positive stock recommendation on the pharma ..."
Pages
70
Language
English
Published on
22/06/22
You may also be interested by these reports :
06/11/26
Genmab’s sales missed expectations, but profitability significantly exceeded expectations. Growth was driven by contributions from most offerings, ...
06/11/26
Sanofi’s growth in recent years has been single-handedly driven by its cornerstone immunology treatment Dupixent, though there has been some support ...
06/11/26
Novonesis delivered an in-line Q3 26, with revenue and adjusted EBITDA marginally ahead of consensus. Food & Beverages (F&B) accelerated to 14%, ...
05/11/26
The Q3 qualitative update did not materially change the full-year outlook, as Branded’s strong momentum made up for the relative weakness in ...